Feb 27 (Reuters) - Maia Biotechnology Inc MAIA.A:
MAIA BIOTECHNOLOGY INC: LANS TO INITIATE A PHASE 3 PIVOTAL TRIAL IN 2025, NAMED THIO-104
MAIA BIOTECHNOLOGY EXPECTS TO BEGIN ENROLLING PATIENTS IN THIO-104 IN SECOND HALF OF 2025 IN SELECT COUNTRIES IN ASIA, EUROPE, U.S
Source text: [ID:n0001493152-25-008540]
Further company coverage: MAIA.A